Intervenční studie o grafenu s kognitivním stavem u starších dospělých
This study was a 4-week facility-level cluster-controlled trial examining whether a graphene-based far-infrared intervention could improve cognitive status among older adults living in long-term care facilities. Five facilities were assigned to one of three study conditions: a graphene-based far-infrared intervention (GFII), a thermal-effects control (TEC) delivered using an electrically heated cap at the same nominal temperature, or a blank control condition without intervention. Participants in the GFII and TEC groups received one 40-minute session daily for 4 weeks. Cognitive outcomes were assessed at baseline, after approximately 2 and 4 weeks of intervention, and at a 4-week post-intervention follow-up. Depressive and anxiety symptoms were also assessed as exploratory outcomes, although they were not the primary focus of the study. The study aimed to examine whether GFII could improve cognitive status beyond the effects of thermal stimulation alone or no intervention.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100101
- Institute of Psychology, Chinese Academy of Sciences
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Aged 55 years or older
- Residing in one of the participating long-term care facilities
- Able to communicate in daily life
- Willing to participate in the assigned study procedures and repeated assessments
Exclusion Criteria:
- Reporting no subjective cognitive decline on any item of the subjective cognitive decline questionnaire
- Having a medical condition that precluded localized head heating
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Graphene far infrared intervention group
Participants received a graphene-based far-infrared intervention (GFII) using a wearable cap set to a nominal temperature of 40°C. Trained caregivers assisted participants with one 40-minute session daily for 4 weeks of active intervention. Participants could sit, lie down, or undertake routine activities during each session. |
The GFII was delivered using a custom wearable cap comprising a flexible cap body with graphene-coated elements, a temperature controller, and an external power adapter. The cap covered the frontal, temporal, and occipital scalp regions and emitted far-infrared radiation primarily within the 4-14 μm range. The device was operated at a nominal temperature of 40°C. Participants received one 40-minute session daily for 4 weeks of active intervention under the assistance and supervision of trained caregivers.
Ostatní jména:
|
|
Aktivní komparátor: Thermal-Effects Control Group
Participants received conventional electrical heating using a commercially available heated cap set to the same nominal temperature of 40°C. The intervention followed the same schedule, 40-minute session duration, and caregiver-assistance procedures as the GFII condition. |
The thermal-effects control was delivered using a commercially available electrically heated cap without graphene-based far-infrared-emitting elements. The cap was operated at the same nominal temperature of 40°C and followed the same intervention schedule, 40-minute session duration, and caregiver-assistance procedures as the GFII condition.
Ostatní jména:
|
|
Žádný zásah: Blank Control Group
Participants received no cap-based intervention and continued their usual daily routines during the study period. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Subjective Cognitive Decline (SCD) Score
Časové okno: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Subjective cognitive decline was assessed using a 10-item multidomain, example-assisted questionnaire. Participants rated perceived cognitive change relative to 1-2 years earlier on a three-point scale ranging from 1 (no decline) to 3 (obvious decline). Total scores range from 10 to 30, with higher scores indicating greater subjective cognitive decline. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
|
Mini-Montreal Cognitive Assessment (Mini-MoCA) Score
Časové okno: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Objective cognitive performance was assessed using the Mini-Montreal Cognitive Assessment (Mini-MoCA), which evaluates visuospatial and executive function, attention, language, abstraction, delayed recall, and orientation. Raw scores range from 0 to 17. Following the scoring instructions, one point was added for participants with fewer than 12 years of education, yielding an education-adjusted score range of 0 to 18. Higher scores indicate better cognitive performance. Scores were analyzed continuously and were not used for clinical diagnosis. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Patient Health Questionnaire-9 (PHQ-9) Score
Časové okno: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Depressive symptoms were assessed using the nine-item Patient Health Questionnaire (PHQ-9). Each item is scored from 0 (not at all) to 3 (nearly every day) based on the frequency of depressive symptoms during the preceding 2 weeks. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. Scores of 10 or higher indicate clinically relevant depressive symptoms. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
|
Generalized Anxiety Disorder-7 (GAD-7) Score
Časové okno: Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Anxiety symptoms were assessed using the Chinese version of the seven-item Generalized Anxiety Disorder scale (GAD-7). Each item is scored from 0 (not at all) to 3 (nearly every day) based on the frequency of anxiety symptoms during the preceding 2 weeks. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. Scores of 10 or higher indicate clinically relevant anxiety symptoms. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
Další identifikační čísla studie
- 2023YFC3605304-1
- 2023YFC3605304 (Jiné číslo grantu/financování: National Key Research and Development projects)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
De-identified participant-level clinical outcome data underlying the findings reported in the publication will be available from the corresponding author upon reasonable request. Access to biomarker data will be considered separately, subject to ethical approval, data-use agreements, and applicable privacy requirements. Potentially identifying information will be withheld or minimized to protect participant privacy.
Časový rámec sdílení IPD
Beginning at publication and continuing for 3 years thereafter.
Kritéria přístupu pro sdílení IPD
Data will be considered for sharing with qualified researchers for noncommercial research purposes, including verification of the reported findings. Requests must include an appropriate research proposal and will be subject to applicable ethical and institutional requirements and a data-use agreement. Requests should be directed to the corresponding author.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .